Entering text into the input field will update the search result below

Sellas Life Sciences to launch registrational study of galinpepimut-S in AML; shares up 10% premarket

  • SELLAS Life Sciences (NASDAQ:SLS) is up 10% premarket on modest volume on the heels of its announcement that it plans to proceed with a pivotal Phase 3 clinical trial evaluating lead candidate galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line antileukemic therapy.
  • GPS has Fast Track and Orphan Drug status in the U.S. for the indication. The primary endpoint of the 116-subject open-label study will be overall survival (OS).
  • GPS, licensed from Memorial Sloan Kettering Cancer Center, targets a protein called Wilms Tumor 1 (WT1) which plays a key role in cell growth.

Recommended For You

About SLS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SLS--
SELLAS Life Sciences Group, Inc.